Graph takes few seconds to load...
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer’s and Parkinson’s diseases.
Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
| Annual Data | Millions of US $ except per share data |
|---|
| Cash on hand |
| Receivables |
| Inventory |
| Pre-Paid Expenses |
| Other Current Assets |
| Total Current Assets |
| Property, Plant, And Equipment |
| Long-Term Investments |
| Goodwill And Intangible Assets |
| Other Long-Term Assets |
| Total Long-Term Assets |
| Total Assets |
| Total Current Liabilities |
| Long Term Debt |
| Other Non-Current Liabilities |
| Total Long Term Liabilities |
| Total Liabilities |
| Common Stock Net |
| Retained Earnings (Accumulated Deficit) |
| Comprehensive Income |
| Other Share Holders Equity |
| Share Holder Equity |
| Total Liabilities And Share Holders Equity |
